Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138500 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02138500 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 5 participants.
The verdict
NCT02138500, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will see how PF-06372865, an experimental drug distributes in the brain after one dose of PF-06372865 is administered orally to healthy volunteer subjects. The study will also evaluate the safety and tolerability of PF-06372865in these subjects and will measure the level of PF-06372865 in the blood.
Interventions
- DRUG PF-06372865
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138500
The ClinicalTrials.gov registry entry for NCT02138500 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06372865 is the first listed.
NCT02138500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138500 about?
NCT02138500 is a clinical study titled "A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865". This study will see how PF-06372865, an experimental drug distributes in the brain after one dose of PF-06372865 is administered orally to healthy volunteer subjects. The study will also evaluate the safety and tolerability of PF-06372865in these subjects and will measure the level of PF-06372865 in...
What is the current status of trial NCT02138500?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2014-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02138500?
The interventions under investigation include: PF-06372865 (DRUG).
Who is sponsoring clinical trial NCT02138500?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.